Dr. Jeffy James Kalavelil, MD

Dr. Kalavelil practices at White Plains Hospital in White Plains, New York, part of Montefiore Einstein.

Dr. Kalavelil's NPI, 1750724043, was assigned on April 17, 2013. Dr. Kalavelil holds New York license 287744.

Dr. Kalavelil's primary practice is White Plains Hospital, at Davis Ave at E Post Road, White Plains, NY 10601 in Westchester County. The practice phone is (914) 681-0600. Dr. Kalavelil also practices at White Plains Hospital, 41 E Post Rd, White Plains, NY 10601.

Dr. Kalavelil's primary practice is White Plains Hospital in White Plains, New York, part of Montefiore Einstein. Dr. Kalavelil is also affiliated with Rome Health Hospital. The medical group on file is East Post Road Medical Services PC. Dmand AI also links Dr. Kalavelil to 4 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kalavelil practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Kalavelil's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Kalavelil is licensed in New York.

CMS data shows 776 Medicare services from Dr. Kalavelil across 4 procedure codes in 2024, for 481 Medicare patients. Medicare paid $83,571 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 481 Medicare patients who saw Dr. Kalavelil in 2024. The largest group is 75 to 84, with 165 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kalavelil's median patient age at 78, with 58% women.

In 2024, Dr. Kalavelil wrote 227 Medicare Part D claims for 106 patients. 85% of them were for generic drugs. CMS names the drug for 31 of them, across 2 drugs with 11 or more claims each, at $189 in total drug cost. In 2023, CMS named 49 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Kalavelil for performance year 2024, reported as part of a group. Dr. Kalavelil accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kalavelil as offering telehealth.

CMS Open Payments shows 19 general payments to Dr. Kalavelil from 9 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $552.